Sarepta Wins Gene-Therapy Patent Trial

In December 2024, a Delaware federal jury found a patent asserted by Sarepta Therapeutics, Inc. to be valid and awarded Sarepta $115 million in damages concerning its VYONDYS 53 gene therapy for treating Duchenne muscular dystrophy (DMD).  The jury also found a patent asserted by adversary Nippon Shinyaku Co. Ltd. to be invalid.  Alongside co-counsel from Finnegan Henderson and Latham & Watkins, Morris Nichols attorneys Jack Blumenfeld, Rodger Smith, and Megan Dellinger represented Sarepta.